There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Foghorn Therapeutics (FHTX – Research Report), Sensus Healthcare (SRTS – Research Report) and Curis (CRIS – Research Report) with bullish sentiments.
Foghorn Therapeutics (FHTX)
H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Foghorn Therapeutics today and set a price target of $20.00. The company’s shares closed last Thursday at $4.85.
According to TipRanks.com, Fein is a 4-star analyst with an average return of
Currently, the analyst consensus on Foghorn Therapeutics is a Moderate Buy with an average price target of $13.00.
See today’s best-performing stocks on TipRanks >>
Sensus Healthcare (SRTS)
In a report released today, Yi Chen from H.C. Wainwright reiterated a Buy rating on Sensus Healthcare, with a price target of $8.00. The company’s shares closed last Thursday at $3.65.
According to TipRanks.com, Chen is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Sensus Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $6.00, which is a 65.7% upside from current levels. In a report released yesterday, Craig-Hallum also assigned a Buy rating to the stock.
Curis (CRIS)
H.C. Wainwright analyst Edward White reiterated a Buy rating on Curis today and set a price target of $26.00. The company’s shares closed last Thursday at $10.65.
According to TipRanks.com, White has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Curis with a $22.33 average price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on FHTX:
